THE ANATOMY OF OUR SUCCESS. Denbufylline Augmentin Eminase Tagamet Fenoldopam
Nabumetone
It's marked by a rich history of breakthrough therapy, Augmentin
ΛΛ
pharmaceuticals. Drugs like Tagamet for ulcer
to treat bacterial infections and Eminase to treat myocardial infarction. And promising
drugs in development for the treatment of central nervous system (denbufylline), kidney (fenoldopam) and rheumatologic (nabumetone) disorders. At SmithKline Beecham, developing these drugs through innovative research and smart business makes us who we are today - a $7 billion global pharmaceutical and health care organization. One where scientific expertise and superior technological resources are found alongside caring people dedicated to improving our quality of life. We're always looking for more people like this. Scientists who feel strongly about their careers and want to pursue them in a progressive and opportunity-filled environment. If you're one such individual, write us at: SmithKline
f^"^
Beecham Pharmaceuticals, CEI, P.O. Box 1539, King
Λ Ι 1
of Prussia, PA 19406. We are an Equal Opportunity
Employer, M/F/H/V.
CIRCLE 20 ON READER SERVICE CARD
SmithKline BeechUfTI
Pharmaceuticals
